Conditions: Small Cell Lung Cancer
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 64
Healthy volunteers: no

Brief summary:
This study was a Phase I/II trial primarily focused on efficacy of BB-10901 in relapsed small cell lung cancer and other solid tumors.

Detailed description:
The Phase II efficacy expansion was restricted to SCLC patients with relapsed disease and the MTD was determined by the Phase I portion of the trial (60mg/m2).

Arms:
arm 1: None arm 2: None arm 3: None arm 4: None arm 5: Phase I and Phase II were consecutive and sequential. Different patients received the 60mg/m2 dose in Phase I and in Phase II. arm 6: None arm 7: None

Interventions: intervention 1: BB-10901
Intervention descriptions: intervention 1: I.V. Infusion - See "Arms" for dosage - Once/Week for three weeks - Until Progression of disease.

Protocol document: